Perceptions have shifted dramatically in the past few years on the therapeutic value of illicit drugs such as ecstasy. But questions still linger about what FDA approval might look like.

For Rick Doblin, 2023 could be a landmark year: the year that the US government decides whether it will allow the use of hallucinogenic drugs to treat mental illness.
Doblin, who is based in Belmont…